Leonard Zehr, Author at BioTuesdays

Feature

Apollomics focused on difficult-to-treat cancers using precision medicine

Apollomics (NASDAQ:APLM) is developing a pipeline of nine novel drug candidates across multiple programs, six of which are now in the clinical stage of development and two in late-stage studies.

August 8, 2023

Developments

Anixa opens enrollment for Keytruda arm in breast cancer vaccine trial

Anixa Biosciences’ (NASDAQ:ANIX) partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the company’s breast cancer vaccine with Keytruda. The treatment arm is an...

August 7, 2023

Feature

ImmunoBrain thinking outside the brain to defeat neurodegenerative diseases

Closely-held ImmunoBrain Checkpoint, with its R&D team in Israel, is pursuing a unique approach that targets the peripheral immune system, rather than directly targeting the brain in patients suffering from Alzheimer’s...

August 1, 2023

Feature

Anixa vaccines targeting unique mechanism in breast, ovarian cancer

Anixa Biosciences (NASDAQ:ANIX) is targeting a unique technology in two early-stage, first-in-class prophylactic cancer vaccines with the potential to prevent cancer cells from forming into breast and ovarian tumors.

July 25, 2023

Feature

Transforming lives with 3D-printed prosthetic hand

As CEO of the Victoria Hand Project, a charity spun out of the University of Victoria in British Columbia, Michael Peirone is a jack of all trades: engineering, operations, IP, business strategy, fundraising and...

July 18, 2023

Feature

Monogram next gen robot seeks to disrupt orthopedic market

Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...

July 11, 2023

Feature

Cantex’s azeliragon in cancer, prevention of acute kidney injury trials

Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...

July 4, 2023

Feature

Chinook on a mission to change the course of kidney care

Chinook Therapeutics (NASDAQ:KDNY), which is developing three drug candidates to change the course of kidney care as well as a precision medicine pipeline of R&D programs, received a shot in the arm this month when...

June 27, 2023

Feature

Centessa focused on asset-centric, patient-centric drug development

Centessa Pharmaceuticals (NASDAQ:CNTA) is developing a portfolio of innovative drug candidates with small, focused R&D teams, a model it calls “asset-centric.”

June 20, 2023

Feature

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.

June 13, 2023

Author - Leonard Zehr

Apollomics focused on difficult-to-treat cancers using precision medicine

Anixa opens enrollment for Keytruda arm in breast cancer vaccine trial

ImmunoBrain thinking outside the brain to defeat neurodegenerative diseases

Anixa vaccines targeting unique mechanism in breast, ovarian cancer

Transforming lives with 3D-printed prosthetic hand

Monogram next gen robot seeks to disrupt orthopedic market

Cantex’s azeliragon in cancer, prevention of acute kidney injury trials

Chinook on a mission to change the course of kidney care

Centessa focused on asset-centric, patient-centric drug development

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

General

More